Del Nogal-Avila Maria, Donoro-Blazquez Hector, Saha Manish K, Marshall Caroline B, Clement Lionel C, Macé Camille E A, Chugh Sumant S
Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F63-5. doi: 10.1152/ajprenal.00245.2016. Epub 2016 May 4.
Improved understanding of glomerular disease mechanisms over the past decade has led to the emergence of new and targeted therapeutic strategies for chronic kidney disease (CKD). Most promising among these are the administration of recombinant mutated human angiopoietin-like 4, sialic acid-related sugars that induce sialylation in vivo, compounds related to Bis-T-23, and immune depletion of the soluble urokinase receptor from the circulation. Taking these therapeutic strategies into clinical trials will be the first step away from repurposed and relatively toxic drugs currently used for treating kidney disease.
在过去十年中，对肾小球疾病机制的深入了解催生了针对慢性肾脏病（CKD）的新型靶向治疗策略。其中最有前景的包括给予重组突变型人血管生成素样4、能在体内诱导唾液酸化的唾液酸相关糖类、与Bis-T-23相关的化合物，以及从循环中免疫清除可溶性尿激酶受体。将这些治疗策略引入临床试验将是摆脱目前用于治疗肾脏疾病的重新利用且毒性相对较大的药物的第一步。
